MedTrace Logo

Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization

NCT07642960 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-06-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization.

The main questions it aims to answer are:

Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients?

Participants will:

Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms.

Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.

Conditions

  • Corneal Neovascularisation

Interventions

PROCEDURE

Fine-needle diathermy

Fine-needle diathermy is performed under an operating microscope using a 10-0 nylon needle and low-power monopolar diathermy to occlude corneal neovessels.

DRUG

Bevacizumab

Bevacizumab 2.5 mg/0.1 mL is administered by subconjunctival injection adjacent to the treated corneal neovessels immediately after fine-needle diathermy.

Sponsors & Collaborators

  • HoChiMinh City Eye Hospital

    lead OTHER

Principal Investigators

  • Minh Nhat Le, Master of Ophthalmology · HoChiMinh City Eye Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2028-04-01
Completion
2028-04-01

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07642960 on ClinicalTrials.gov